Trelegy Ellipta
*Company:
GlaxoSmithKline (Ireland) LtdStatus:
No Recent UpdateLegal Category:
Product subject to medical prescription which may be renewed (B)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 01 August 2024
File name
ie-spc-trelegyellipta-issue10draft1-Master.pdf
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Change to section 4.9 - Reporting of suspected adverse reactions
Updated on 01 August 2024
File name
ie-pl-trelegyellipta-issue12draft1-Master.pdf
Reasons for updating
- Change to section 4 - how to report a side effect
Free text change information supplied by the pharmaceutical company
Change to section 4 - Reporting of side effects
Updated on 07 September 2023
File name
ieukni-spc-combined-trelegyellipta-issue9draft1-compendia.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
- Improved presentation of SPC
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
1. New rare adverse reactions (hyperglycemia, anxiety, tremor, palpitations and muscle spasms) has been added to the section 4.8. Undesirable effects
2. Minor editorial changes has been made to the section 4.4, 4.9 and 5.3 to improve the presentation of SPC
3. Date of the revision of the text has been updated to the section 10.
Updated on 07 September 2023
File name
ieukni-pl-combined-trelegyellipta-issue11draft1-compendia.pdf
Reasons for updating
- Change to section 4 - possible side effects
- Improved presentation of PIL
Updated on 27 February 2023
File name
ieukni-pl-combined-trelegyellipta-issue10draft1.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
Free text change information supplied by the pharmaceutical company
GDSv11 Update:
PIL:
1. Minor corrections to the warnings and precautions of the section 2. What you need to know before you use Trelegy Ellipta
2. Included new adverse reactions (urinary retention and dysuria) in the other side effects of the section4. Possible side effects.
3. Updated the last date of revision of the leaflet
Updated on 27 February 2023
File name
ieukni-spc-combined-trelegyellipta-issue8draft1.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
GDSv11 update
1. Updated the anticholinergic activity of section 4.4. Special warnings and precautions for use
2. Addition of new adverse reactions (Urinary retention and Dysuria) to the section 4.8. Undesirable effects
3. Updated the Section 10 Date of the revision of the text.
Updated on 01 August 2022
File name
ieukni-spc-combined-trelegyellipta-issue7draft1-emc.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 4.9 - Overdose
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 6.4 - Special precautions for storage
- Change to section 6.5 - Nature and contents of container
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 9 - Date of first authorisation/renewal of the authorisation
- Correction of spelling/typing errors
- Removal of Black Inverted Triangle
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 01 August 2022
File name
ieukni-pil-combined-trelegyellipta-issue9draft1-emc.pdf
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 5 - how to store or dispose
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - date of revision
- Removal of Black Inverted Triangle
- Correction of spelling/typing errors
Updated on 26 November 2021
File name
ieukni-pl-combined-trelegyellipta-issue8draft1-compendia.pdf
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
- Change to other sources of information section
Updated on 26 November 2021
File name
ieukni-spc-combined-trelegyellipta-issue6draft1-compendia.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 18 February 2021
File name
ie-pil-trelegyellipta-issue7draft1-clean - medie.pdf
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
Updated on 22 September 2020
File name
ie-spc-trelegyellipta-issue5draft1-medie.pdf
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 22 September 2020
File name
ie-pil-trelegyellipta-issue6draft1-medie.pdf
Reasons for updating
- Change to section 1 - what the product is used for
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 3 - how to take/use
- Change to section 4 - possible side effects
- Change to section 5 - how to store or dispose
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - date of revision
Updated on 19 December 2019
File name
ie-spc-trelegyellipta-issue4draft1-clean-medicines.ie.pdf
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 19 December 2019
File name
ie-pil-trelegyellipta-issue5draft1-clean-medicines.ie.pdf
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Updated on 02 January 2019
File name
ie-pil-trelegy-issue4draft1-MED.IE.pdf
Reasons for updating
- Change to section 4 - how to report a side effect
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
Updated on 21 November 2018
File name
ukie-pil-trelegy-issue3draft1 for Meds compendia.pdf
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 21 November 2018
File name
ukie-spc-trelegy-issue3draft1 for Meds.ie.pdf
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Section 4.1 - Addition of indication
Section 4.8 - cross reference to the effects on symptoms is added based on the results of studies
Section 5.1 - additional information related to the clinical efficacy based on the results of studies
Section 5.2 - additional information related to the pharmacokinetic properties based on the results of studies
Section 5.3 - additional information related to the pre-clinical safety data based on the results of studies
Updated on 08 June 2018
File name
ie-spc-trelegy for medicine.ie.docx
Reasons for updating
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
- Improved presentation of SPC
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
– Addition of ATC code to Section 5.1 of the SmPC;
– Editorial changes to:
– spelt out the name of the marketing authorisation holder in full
– add zeros in the marketing authorisation numbers
Updated on 07 June 2018
File name
ie-pl-trelegy for medsie.pdf
Reasons for updating
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
- Change to further information section
Updated on 09 March 2018
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 08 March 2018
File name
PIL_17428_566.pdf
Reasons for updating
- New PIL for new product